Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics

[1]  H. Heinsen,et al.  Cortical and striatal neurone number in Huntington's disease , 2004, Acta Neuropathologica.

[2]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[3]  S. Schiffmann,et al.  A Dual Role of Adenosine A2A Receptors in 3-Nitropropionic Acid-Induced Striatal Lesions: Implications for the Neuroprotective Potential of A2A Antagonists , 2003, The Journal of Neuroscience.

[4]  Zhang Jin.  Neuroprotective strategies for basal ganglia degeneration , 2003 .

[5]  P. d'Alcantara,et al.  The Adenosine A1 Receptor Agonist Adenosine Amine Congener Exerts a Neuroprotective Effect against the Development of Striatal Lesions and Motor Impairments in the 3-Nitropropionic Acid Model of Neurotoxicity , 2002, The Journal of Neuroscience.

[6]  S. Schiffmann,et al.  Striatal and Cortical Neurochemical Changes Induced by Chronic Metabolic Compromise in the 3-Nitropropionic Model of Huntington's Disease , 2002, Neurobiology of Disease.

[7]  James R. Burke,et al.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.

[8]  K. Lindenberg,et al.  Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. , 2002, Brain : a journal of neurology.

[9]  H. Robertson,et al.  Maintained improvement with minocycline of a patient with advanced Huntington's disease , 2002, Journal of psychopharmacology.

[10]  L. Ellerby,et al.  Calpain Activation in Huntington's Disease , 2002, The Journal of Neuroscience.

[11]  Fabrice P Cordelières,et al.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.

[12]  Dimitri Krainc,et al.  Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.

[13]  Christopher A. Ross,et al.  Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length , 2002, The Journal of Neuroscience.

[14]  A. Ascherio,et al.  Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. , 2002, Neurology.

[15]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.

[16]  M. Falchi,et al.  Blockade of Striatal Adenosine A2A Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxicity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum , 2002, The Journal of Neuroscience.

[17]  A. Hackam,et al.  Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi , 2002, Nature Cell Biology.

[18]  K. Ikeda,et al.  Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease , 2002, Journal of neurochemistry.

[19]  M. Chesselet,et al.  Mouse models of Huntington's disease. , 2002, Trends in pharmacological sciences.

[20]  A. Ohta,et al.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage , 2001, Nature.

[21]  B. Fredholm,et al.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.

[22]  P. d'Alcantara,et al.  Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission , 2001, Neuroscience.

[23]  F. Chéruel,et al.  Perseverative Behavior Underlying Attentional Set-Shifting Deficits in Rats Chronically Treated with the Neurotoxin 3-Nitropropionic Acid , 2001, Experimental Neurology.

[24]  David Blum,et al.  Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.

[25]  Elan D. Louis,et al.  Merritt's Neurology , 2001 .

[26]  B. Fredholm,et al.  Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Greengard,et al.  Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine , 2001, The Journal of Neuroscience.

[28]  P. Popoli,et al.  SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum. , 2001, European journal of pharmacology.

[29]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[30]  S. Schiffmann,et al.  Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat , 2001, Neuroreport.

[31]  W. Turski,et al.  Protective effect of adenosine receptor agonists in a new model of epilepsy – seizures evoked by mitochondrial toxin, 3-nitropropionic acid, in mice , 2001, Neuroscience Letters.

[32]  S. Latini,et al.  Adenosine Extracellular Brain Concentrations and Role of A2A Receptors in Ischemia , 2001, Annals of the New York Academy of Sciences.

[33]  James Peeling,et al.  Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage , 2001, Annals of neurology.

[34]  N. Déglon,et al.  Neuroprotective Effect of a CNTF-Expressing Lentiviral Vector in the Quinolinic Acid Rat Model of Huntington's Disease , 2001, Neurobiology of Disease.

[35]  M. Schwarzschild,et al.  Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[36]  Knutsen Lj,et al.  KW-6002 (Kyowa Hakko Kogyo). , 2001 .

[37]  K. Varani,et al.  Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  C A Ross,et al.  Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.

[39]  J. Linden,et al.  Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum , 2001, The Journal of comparative neurology.

[40]  Elena Cattaneo,et al.  Loss of normal huntingtin function: new developments in Huntington's disease research , 2001, Trends in Neurosciences.

[41]  P G Bhide,et al.  Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain , 2001, Journal of neuropathology and experimental neurology.

[42]  H. Kase.  New Aspects of Physiological and Pathophysiological Functions of Adenosine A2A Receptor in Basal Ganglia , 2001, Bioscience, biotechnology, and biochemistry.

[43]  T. Dunwiddie,et al.  The Role and Regulation of Adenosine in the Central Nervous System , 2022 .

[44]  Anne-Catherine Bachoud-Lévi,et al.  Motor and cognitive improvements in patients with Huntington's disease after neural transplantation , 2000, The Lancet.

[45]  M. Ochi,et al.  Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. , 2000, European journal of pharmacology.

[46]  Michael S. Levine,et al.  Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.

[47]  CGS 21680 exerts marked antidystonic effects in a genetic model of paroxysmal dyskinesia. , 2000, European journal of pharmacology.

[48]  Alexandre de Mendonça,et al.  Adenosine: does it have a neuroprotective role after all? , 2000, Brain Research Reviews.

[49]  J. Cha,et al.  Transcriptional dysregulation in Huntington’s disease , 2000, Trends in Neurosciences.

[50]  H. Zimmermann.  Extracellular metabolism of ATP and other nucleotides , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[51]  F. Pedata,et al.  Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats , 2000, Neuroreport.

[52]  M. Beal.  Energetics in the pathogenesis of neurodegenerative diseases , 2000, Trends in Neurosciences.

[53]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  W. Maragos,et al.  Neuronal cell death in Huntington’s disease: a potential role for dopamine , 2000, Trends in Neurosciences.

[55]  T. Itakura,et al.  Fetal tissue transplants in animal models of Huntington’s disease: the effects on damaged neuronal circuitry and behavioral deficits , 2000, Progress in Neurobiology.

[56]  J. Bloch,et al.  Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. , 2000, Human gene therapy.

[57]  A. Hackam,et al.  Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3 , 2000, The Journal of Neuroscience.

[58]  M. Dragunow,et al.  The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.

[59]  P. Gluckman,et al.  Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases , 2000, Progress in Neurobiology.

[60]  M. Chesselet,et al.  Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.

[61]  A. Cooper,et al.  The selective vulnerability of striatopallidal neurons , 1999, Progress in Neurobiology.

[62]  Françoise Condé,et al.  Replicating Huntington's disease phenotype in experimental animals , 1999, Progress in Neurobiology.

[63]  Carlos Cepeda,et al.  Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.

[64]  P. Svenningsson,et al.  Distribution, biochemistry and function of striatal adenosine A2A receptors , 1999, Progress in Neurobiology.

[65]  M. Moskowitz,et al.  A2A Adenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice , 1999, The Journal of Neuroscience.

[66]  S. Snyder,et al.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization , 1999, Nature Medicine.

[67]  J. M. Boutell,et al.  Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. , 1999, Human molecular genetics.

[68]  M. Judge,et al.  N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. , 1999, Journal of medicinal chemistry.

[69]  Y. Bordelon,et al.  Early effects of intrastriatal injections of quinolinic acid on microtubule-associated protein-2 and neuropeptides in rat basal ganglia , 1999, Neuroscience.

[70]  S. W. Davies,et al.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[71]  R. Corradetti,et al.  Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices , 1999, British journal of pharmacology.

[72]  L. Grégoire,et al.  Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys , 1999, Neurology.

[73]  Claire-Anne Gutekunst,et al.  A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.

[74]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[75]  F. Pedata,et al.  Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. , 1999, Neuroreport.

[76]  B. Fredholm,et al.  Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. , 1999, Pharmacological reviews.

[77]  E. Ongini,et al.  Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats , 1998, Neuroreport.

[78]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[79]  G Burnstock,et al.  Receptors for purines and pyrimidines. , 1998, Pharmacological reviews.

[80]  M. Jarvis,et al.  Inhibition of adenosine kinase during oxygen-glucose deprivation in rat cortical neuronal cultures , 1998, Neuroscience Letters.

[81]  T. Stone,et al.  Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist , 1998, Brain Research.

[82]  J. Geiger,et al.  Levels of endogenous adenosine in rat striatum. I. Regulation by ionotropic glutamate receptors, nitric oxide and free radicals. , 1998, The Journal of pharmacology and experimental therapeutics.

[83]  P. Jenner,et al.  Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys , 1998, Annals of neurology.

[84]  H. Haas,et al.  Adenosine A1 receptor-mediated depression of corticostriatal and thalamostriatal glutamatergic synaptic potentials in vitro , 1997, Brain Research.

[85]  T. Dunwiddie,et al.  Adenine Nucleotides Undergo Rapid, Quantitative Conversion to Adenosine in the Extracellular Space in Rat Hippocampus , 1997, The Journal of Neuroscience.

[86]  P. Jenner,et al.  Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. , 1997, Trends in pharmacological sciences.

[87]  K. Jacobson,et al.  Adenosine A1 Receptor Agonists as Clinically Viable Agents for Treatment of Ischemic Brain Disorders , 1997, Annals of the New York Academy of Sciences.

[88]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[89]  S. Palfi,et al.  Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats , 1997, Neuroscience.

[90]  S. Schiffmann,et al.  Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor , 1997, Nature.

[91]  J. Meno,et al.  Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide , 1997, Brain Research.

[92]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[93]  F. Marchlinski,et al.  Adenosine as an antiarrhythmic agent. , 1997, The American journal of cardiology.

[94]  P. Svenningsson,et al.  Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate–putamen and nucleus accumbens , 1997, Neuroscience.

[95]  A Weindl,et al.  Changes of NMDA Receptor Subunit (NR1, NR2B) and Glutamate Transporter (GLT1) mRNA Expression in Huntington's Disease—An In Situ Hybridization Study , 1997, Journal of neuropathology and experimental neurology.

[96]  E. Ongini,et al.  Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. , 1997, European journal of pharmacology.

[97]  K. Jacobson,et al.  Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. , 1996, European journal of pharmacology.

[98]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[99]  M. Hayden,et al.  Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract , 1996, Nature Genetics.

[100]  U. Ungerstedt,et al.  Dopamine D1 Receptor‐mediated Facilitation of GABAergic Neurotransmission in the Rat Strioentopeduncular Pathway and its Modulation by Adenosine A1 Receptor‐mediated Mechanisms , 1996, The European journal of neuroscience.

[101]  B. Fredholm,et al.  Adenosine receptor ligands: differences with acute versus chronic treatment. , 1996, Trends in pharmacological sciences.

[102]  J. Geiger,et al.  Brain regional levels of adenosine and adenosine nucleotides in rats killed by high-energy focused microwave irradiation , 1996, Journal of Neuroscience Methods.

[103]  P. White,et al.  Functional characterization of adenosine receptors in the nucleus tractus solitarius mediating hypotensive responses in the rat , 1996, British journal of pharmacology.

[104]  B. Fredholm.  Chapter 11 Adenosine and Neuroprotection , 1996 .

[105]  J. Phillis.  The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil , 1995, Brain Research.

[106]  P. Popoli,et al.  Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. , 1995, European journal of pharmacology.

[107]  E. Richfield,et al.  Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients , 1995, Annals of neurology.

[108]  D. Colussi,et al.  Cardiovascular and antilipolytic effects of the adenosine agonist GR79236. , 1995, Pharmacology.

[109]  A. Mendonça,et al.  Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation , 1995 .

[110]  S. Rivkees,et al.  Immunohistochemical detection of A1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia , 1995, Brain Research.

[111]  P. Strong,et al.  Characterization of the adenosine receptors mediating hypothermia in the conscious mouse , 1994, British journal of pharmacology.

[112]  B. Fredholm,et al.  Modulation of nerve and glial function by adenosine--role in the development of ischemic damage. , 1994, The International journal of biochemistry.

[113]  R. Nicoll,et al.  Release of adenosine by activation of NMDA receptors in the hippocampus. , 1994, Science.

[114]  J. Daval,et al.  Opposite effects of cyclohexyladenosine and theophylline on hypoxic damage in cultured neurons , 1994, Neuroscience Letters.

[115]  K. Jacobson,et al.  Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. , 1994, European journal of pharmacology.

[116]  T. Dunwiddie,et al.  Extracellular adenosine concentrations in hippocampal brain slices and the tonic inhibitory modulation of evoked excitatory responses. , 1994, The Journal of pharmacology and experimental therapeutics.

[117]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[118]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[119]  M. Williams.  Purinergic drugs: Opportunities in the 1990s , 1993 .

[120]  J. Vanderhaeghen,et al.  Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[121]  J. Spillane,et al.  Choreiform Movements Observed in an 8-Year-Old Child Following Use Of an Oral Theophylline Preparation , 1992, Clinical pediatrics.

[122]  E. M. Adler,et al.  Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. , 1992, Brain research. Molecular brain research.

[123]  V. Gribkoff,et al.  Hypoxia produces cell death in the rat hippocampus in the presence of an A1 adenosine receptor antagonist: An anatomical and behavioral study , 1992, Neuroscience.

[124]  J. Penney,et al.  Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.

[125]  B B Fredholm,et al.  Neuroprotective role of adenosine in cerebral ischaemia. , 1992, Trends in pharmacological sciences.

[126]  Christopher A. Ross,et al.  Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease , 1991, Neuroscience Letters.

[127]  S. Schiffmann,et al.  Striatal Restricted Adenosine A2 Receptor (RDC8) Is Expressed by Enkephalin but Not by Substance P Neurons: An In Situ Hybridization Histochemistry Study , 1991, Journal of neurochemistry.

[128]  S. Rivkees,et al.  Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. , 1991, Molecular endocrinology.

[129]  R. Albin,et al.  Acute dyskinesias in young asthmatics treated with theophylline. , 1991, Pediatric neurology.

[130]  U. Ungerstedt,et al.  Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice. , 1991, European journal of pharmacology.

[131]  S. Schiffmann,et al.  A cloned G protein-coupled protein with a distribution restricted to striatal medium-sized neurons. Possible relationship with D1 dopamine receptor , 1990, Brain Research.

[132]  J. Fowler.  Adenosine antagonists alter the synaptic response to in vitro ischemia in the rat hippocampus , 1990, Brain Research.

[133]  J. Fowler.  Adenosine antagonists delay hypoxia-induced depression of neuronal activity in hippocampal brain slice , 1989, Brain Research.

[134]  J. Dambrosia,et al.  Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of gerbil hippocampus. , 1988, Stroke.

[135]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[136]  B. Fredholm,et al.  How does adenosine inhibit transmitter release? , 1988, Trends in pharmacological sciences.

[137]  B. Fredholm,et al.  Central versus peripheral mediation of responses to adenosine receptor agonists: Evidence against a central mode of action , 1987, Brain Research.

[138]  A. Young,et al.  A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.

[139]  B. Fredholm,et al.  Are methylxanthine effects due to antagonism of endogenous adenosine , 1979 .